BEGIN:VCALENDAR VERSION:2.0 PRODID:-//jEvents 2.0 for Joomla//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VEVENT UID:5f898d91c1ba50c4a80f9ec96bfb58f540 CATEGORIES:IEC Events (for everyone) SUMMARY:IEC at EADV Virtual Congress 2020 DESCRIPTION:
At EADV Virtual Congress 2020 | October 2020
View the IEC virtual symposium to discuss novel systemic t reatments for atopic dermatitis and clinical trial design.
< strong style="font-size: 15px;">PROGRAM CHAIRS
Robert Bisson
nette, MD, Montreal, QC, Canada
Diamant Thaci, MD, Lubeck, Germany
Thomas Bieber, MD, Bonn, Germany
AGENDA
Emma Guttman, MD, IEC President
, New York, NY, USA
Optimizing Clinical Trial Design for AD d
rug development
Robert Bissonnette, MD, IEC President Elect,
Montreal, QC, Canada
Novel Systemic Treatments in Pediatrics
and Placebo Responses in Systemic Trials
Michael Cork, MD, Sh
effield, UK
Monoclonal antibodies targeting Th2 receptors and
cytokines (e.g. IL4R, IL-13 and IL-31)
Thomas Bieber, MD, Bo
nn, Germany
Monoclonal antibodies targeting epithelial-derive
d protein (e.g. IL-17C, IL-33 and TSLP)
Diamant Thaci, MD, L
ubeck, Germany
Monoclonal antibodies with other targets (e.g.
OX40, IL-22 and IL-23) and biomarkers of disease response
E
mma Guttman, MD, New York, NY, USA
Systemic JAK inhibitors
Eric Simpson, MD, Portland, OR, USA
Topical JAK
inhibitors
Jonathan Silverberg, MD, Washington DC, USA
Other systemic treatments
Andreas Wollenberg, MD, Mun
ich, Germany
SPEAKERS
Emma Guttman, MD PhD
Emm
a Guttman, MD PhD, is the Sol and Clara Kest professor of dermatology, vice
chair for research at the Department of Dermatology, and director of both
the Center for Excellence in Eczema and the Laboratory of Inflammatory Skin
Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, Ne
w York.
Guttman’s major focus is atopic dermatitis (AD). She ha s:
She earned her doctor of medicine degree from Sackler in Tel-Aviv, Israel, and a doctor of philosophy degree from Bar-Ilan University in Israe l. After receiving her board certification in dermatology in Israel, Guttma n moved to the United States to pursue a postdoctoral fellowship at The Roc kefeller University in New York, NY, and a second dermatology residency at Weill Cornell Medicine in New York, NY.
In addition to serving as pre sident of the International Eczema Council (IEC), Guttman was elected to th e American Society for Clinical Investigation (ASCI) and the American Acade my of Dermatology (AAD). Among other honors, she received the AAD Young Inv estigator Award in 2011.
Robert Bissonnette, MD FRCPC
Board certifi
ed in dermatology, Dr. Bissonnette is the president of Innovaderm Research—
a contract research organization (CRO) specializing in the design, conduct,
and analysis of clinical trials in various areas of dermatology—in Montrea
l, QC, Canada. He has published more than 150 articles and book chapters an
d gives lectures on various aspects of dermatology at national and internat
ional meetings.
Dr. Bissonnette earned his medical degree from the Un iversity of Montreal, underwent residency training in dermatology at the Un iversity of Montreal, and completed his basic and clinical research trainin g at McGill University and the University of British Columbia. He was an as sociate professor of dermatology at the University of Montreal until 2004.< /p>
Michael J. Cork, BSc, MB, PhD, FRCP
Professor Michael J. Cork is head of Sheffield Dermatology Research; in the Dept. of Infection, Immunity & Cardiovascular Disease; Faculty of Medi cine, Dentistry & Health; at The University of Sheffield, UK. He is a C onsultant Dermatologist to Sheffield Children’s Hospital (SCH) NHS Trust an d to Sheffield Teaching Hospitals (STH) NHS Trust.
He speciali ses in treating children and adults with the most severe atopic dermatitis and sees patients from anywhere in the UK. At Sheffield Children’s Hospital he leads an integrated atopic dermatitis – allergy – psychiatry service, d esigned to manage the most complex patients. He leads clinical trials of ne w treatments for atopic dermatitis at the Clinical Research Facilities at S CH for children and at STH for adults. He is Chief Investigator, in the UK, for many of the trials for new biologics, small molecules and topicals for atopic dermatitis.
With Dr. Simon Danby, they have created a dedicat ed clinical research facility for skin barrier, biomarker research. Their S kin Barrier Team have developed a research facility that has developed a un ique combination of techniques to assess how topical wash products, emollie nts and topical/systemic pharmaceutical agents affect the integrity of the skin barrier and inflammation in normal and AD skin. These biomarkers are u sed to assess the safety and efficacy of treatments for atopic dermatitis. These atopic dermatitis biomarkers are also being used in experimental medi cine clinical trials to stratify patients according to clinical response an d safety parameters. This information can be used to determine how long a t reatment should be used for, the optimum dose, the effect on some comorbidi ties and inform health economic evaluations
Our research group also h as a special interest in the prevention of atopic dermatitis. This involves both mechanistic studies and large collaborative clinical trials. We inves tigate how the environment of a baby interacts with their skin to induce th e development of atopic dermatitis. A major focus is on how topical wash pr oducts, emollients, oils, and water itself, affect the skin barrier and how this leads to the development of atopic dermatitis. This then informs the design of combinations of topical products that will have the optimum effec t on the development and maintenance of the skin barrier.
Thomas Bieber, MD PhD MDRA, is
the chair and director of the University of Bonn’s Department of Dermatolog
y, director and speaker of the Christine Kühne–Center for Allergy Research
and Education, and cofounder of the Center of Translational Medicine (CTM),
a joint research program between the medical faculty of the University of
Bonn’s medical faculty and the German Federal Institute for Drugs and Medic
al Devices (BfArM).
In addition to cli nical dermatology and allergy, Bieber’s scientific focus is in the ontogeny and immunobiology of dendritic cells, their role in atopic dermatitis, in tolerance mechanisms, and in the control of the cutaneous microbiome by the innate immunity.
Bieber studied medicine and received his PhD in biology at Louis Pasteur University in Strasbourg. He also holds a mast er’s degree in drug regulatory affairs (MDRA). He has trained in dermatolog y, allergy, dermatopathology, and occupational dermatology at the departmen ts of Strasbourg and in Munich, Germany.
Diamant Thaçi, MD PhD
Board certified in dermatology and venereology, Dr. Thaçi is a director a
nd full university professor at the Comprehensive Center for Inflammation M
edicine, University of Lübeck in Lübeck, Germany, a role he has held since
2013. He also is chair of the inflammatory board at University Medical Cent
er Schleswig-Holstein in Lübeck. He is a member of the Group for Research a
nd Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) steering commit
tee, International Psoriasis Council (IPC), the IEC, and Skin Inflammation
& Psoriasis International Network (SPIN).
Dr Thaçi’s research has
included immunology and all stages of clinical drug development, with a fo
cus on chronic inflammatory skin diseases such as psoriasis, atopic dermati
tis, and hidradenitis suppurativa. A recipient of the Theodor-Stern Foundat
ion Award for excellence in clinical research, he has been involved in nume
rous investigator-driven trials and acted as main investigator on large num
bers of national and international multicenter trials.
He has publish
ed numerous articles, including in the New England Journal of Medicine and
Lancet; held positions as editor, co-editor, and editorial board member for
several scientific journals; and serves as a scientific reviewer for derma
tological and general medicine journals. He also lectures on dermatology an
d related topics.
Dr. Thaçi earned his medical degree in 1989 from th e University of Pristina in Pristina, Kosovo. He completed his residency in the Department of Dermatology and Venerology at Johann Wolfgang Goethe Uni versity in Frankfurt, Germany. There, he was a senior consulting specialist in dermatology, director of clinical research, and head of the photodermat ology division from 1997 to 2011. In 2011, he was appointed associate profe ssor of dermatology, venereology, and allergology at Goethe University.
Eric Sim
pson, MD MCR
Eric Simpson heads the Department of Dermatology
’s Clinical Studies Unit at Oregon Health & Sciences University. He has
a special interest in chronic inflammatory skin diseases. He is funded by
the National Institutes of Health and industry partners to study new approa
ches to skin disease treatment and prevention. Dr. Simpson regularly instru
cts residents and medical students in dermatology.
He has published m ore than 70 scientific articles in peer-reviewed journals including the New England Journal of Medicine and The Lancet. He is co-chair of the Scientif ic Advisory Committee of the National Eczema Association and is on the exec utive committee of the Harmonizing Outcome Measures in Eczema (HOME), which seeks to improve the quality of eczema research.
An associate professor of dermatology, Jonathan Sil
verberg is the director of clinical research and contact dermatitis at The
George Washington University School of Medicine and Health Sciences in Wash
ington, DC.
His area of clinical subspecialty is inflammatory skin di sease, particularly atopic and contact dermatitis. He has extensive experie nce in the advanced management of atopic dermatitis, hand eczema, chronic i tch, psoriasis, hidradenitis and many other chronic inflammatory skin disor ders. He also is a national expert in allergy patch testing, phototesting, and photopatch testing.
Dr. Silverberg’s publications include more th an 600 peer-reviewed articles, abstracts, and book chapters. He also is the author of Clinical Management of Atopic Dermatitis (2018).
He has be en a local, national, and international principal investigator for numerous clinical trials for novel treatments in atopic dermatitis and other inflam matory disorders. He is the chair of the annual Revolutionizing Atopic Derm atitis global multidisciplinary conference and an associate editor for the Journal of the American Academy of Dermatology, British Journal of Dermatol ogy, and Current Dermatology Reports.
Dr. Silverberg completed his un dergraduate degree, medical school training, doctorate in neuroimmunology, master of public health degree in biostatistics and epidemiology, and inter nship in internal medicine at State University of New York Downstate Medica l Center. He completed his residency training in dermatology at St. Luke’s- Roosevelt Hospital Center and Beth Israel Medical Centers in New York, NY, and served as chief resident during his final year.
An dreas Wollenberg, MD, DrMed, DrHC
DTSTAMP:20240328T131619 DTSTART:20201029T080000Z DTEND:20201031T220000Z SEQUENCE:0 TRANSP:OPAQUE END:VEVENT END:VCALENDAR